Drugs / CX516
CX516
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT00054730 | Jun 2002 → ? | autism, fragile X syndrome | RespireRx | Completed | No outcome recorded |
| Phase 2 | NCT00040443 | Apr 2002 → Aug 2003 | cognitive impairment with or without cerebellar ataxia | RespireRx | Completed | Met primary |
| Phase 2 | NCT00001662 | Dec 1996 → Nov 2005 | Alzheimer disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00235352 | Feb 2002 → Apr 2005 | schizophrenia | North Suffolk Mental Health Association | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00054730 ↗ |
| Known as | Ampalex | “CX516 (Ampalex) is a test drug that affects the AMPA receptors.” NCT00001662 ↗1“CX516 (Ampalex®)” NCT00054730 ↗ |
| Known as | BDP 12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL136800 ↗ |
| Action | Activate | “positive modulation of AMPA receptors” NCT00001662 ↗ |
| Modality | Other / unclassified | “The AMPA receptor positive modulator, CX516, will be added to a stable dose of clozapine, olanzapine or risperidone” NCT00235352 ↗ |
| Route | Oral | “will be administered orally for 12 weeks” NCT00001662 ↗ |